Guido Eibl
Impact in
- Oncology top 1%
- Pancreatic and Hepatic Oncology Research
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
Papers in
- Oncology 39
- Pancreatic and Hepatic Oncology Research 24
-
- Metabolism, Diabetes, and Cancer 13
- Peroxisome Proliferator-Activated Receptors 5
- Co-authors
- O. Joe Hines (43 shared papers)Howard A. Reber (31 shared papers)Enrique Rozengurt (22 shared papers)James Sinnett‐Smith (15 shared papers)Krisztina Kisfalvi (3 shared papers)John P. Duffy (4 shared papers)H. J. Buhr (14 shared papers)Aune Moro (15 shared papers)
- Journals
- Pancreas (18 papers)Cancer Research (7 papers)Surgery (6 papers)PLoS ONE (4 papers)Cancers (4 papers)
- Partner nations
- United StatesGermanyJapan
In The Last Decade
Guido Eibl
100 papers receiving 4.1k citations
Guido Eibl's Hit Papers
Peers
Comparison fields: 5 of 123
- Oncology 1.6k
- Cancer Research 697
- Surgery 973
- Molecular Biology 1.5k
- Pharmacology 310
Countries citing papers authored by Guido Eibl
This map shows the geographic impact of Guido Eibl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guido Eibl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guido Eibl more than expected).
Fields of papers citing papers by Guido Eibl
This network shows the impact of papers produced by Guido Eibl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guido Eibl. The network helps show where Guido Eibl may publish in the future.
Co-authors
The 25 scholars most cited alongside Guido Eibl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 103 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer Hit paper breakdown → | 2017 | 332 |
| 2 | 2009 | 258 | |
| 3 | 2011 | 147 | |
| 4 | 2003 | 143 | |
| 5 | 2018 | 121 | |
| 6 | 2008 | 109 | |
| 7 | 2017 | 105 | |
| 8 | 2003 | 103 | |
| 9 | 2007 | 95 | |
| 10 | 2017 | 94 | |
| 11 | 2001 | 92 | |
| 12 | 2018 | 90 | |
| 13 | 2004 | 89 | |
| 14 | 2005 | 86 | |
| 15 | 2016 | 81 | |
| 16 | 2013 | 74 | |
| 17 | 2009 | 68 | |
| 18 | 2000 | 65 | |
| 19 | 2017 | 64 | |
| 20 | 2000 | 63 |
About Guido Eibl
Guido Eibl is a scholar working on Oncology, Molecular Biology, Surgery, Cancer Research and Pharmacology, having authored 103 papers that have together received 4.2k indexed citations. Recurring topics across this work include Pancreatitis Pathology and Treatment (24 papers), Pancreatic and Hepatic Oncology Research (24 papers), Inflammatory mediators and NSAID effects (15 papers), Metabolism, Diabetes, and Cancer (13 papers), Hippo pathway signaling and YAP/TAZ (7 papers), Cancer, Lipids, and Metabolism (7 papers), Peroxisome Proliferator-Activated Receptors (5 papers) and Eicosanoids and Hypertension Pharmacology (5 papers). The work is most often cited by research in Oncology (1.6k citations), Cancer Research (697 citations), Surgery (973 citations), Molecular Biology (1.5k citations) and Pharmacology (310 citations). Guido Eibl has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include O. Joe Hines, Howard A. Reber, Enrique Rozengurt, James Sinnett‐Smith, Krisztina Kisfalvi, John P. Duffy, H. J. Buhr, Aune Moro, Hui-Hua Chang and Hubert G. Hotz. Their work appears in journals such as Pancreas, Cancer Research, Surgery, PLoS ONE and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.